相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
PARP Inhibitors in Pancreatic Cancer
Timothy J. Brown et al.
CANCER JOURNAL (2021)
Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
Talia Golan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2
Kim A. Reiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
BRCA mutated pancreatic cancer: A change is coming
Michael N. Rosen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2021)
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
S. Lindsey Davis et al.
INVESTIGATIONAL NEW DRUGS (2020)
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta et al.
BRITISH JOURNAL OF CANCER (2020)
HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).
Margaret A. Tempero et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
Eileen M. O'Reilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud et al.
CANCERS (2020)
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
Robert M. Samstein et al.
NATURE CANCER (2020)
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
Ramesh K. Ramanathan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
Zishuo Ian Hu et al.
CANCER MEDICINE (2019)
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
Natalie Cook et al.
BRITISH JOURNAL OF CANCER (2018)
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Maeve A. Lowery et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma
Shoko Takeuchi et al.
SCIENTIFIC REPORTS (2018)
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Maeve A. Lowery et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
Davide Melisi et al.
BRITISH JOURNAL OF CANCER (2018)
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
B. Schultheis et al.
ANNALS OF ONCOLOGY (2017)
Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetes
James Dooley et al.
NATURE GENETICS (2016)
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
J. Bendell et al.
ANNALS OF ONCOLOGY (2015)
Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors
Nerea Urtasun et al.
BMC CANCER (2015)
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
S. Kordes et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
A. H. Ko et al.
CLINICAL CANCER RESEARCH (2015)
Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial
Tatsuya Ioka et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
Herbert I. Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Spring Holter et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer
Soren Mueller et al.
MOLECULAR CANCER (2015)
Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling
Hsiu-Mei Chen et al.
ONCOTARGET (2015)
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study
David B. Zhen et al.
GENETICS IN MEDICINE (2015)
Dual Blockade of Epidermal Growth Factor Receptor and Insulin-Like Growth Factor Receptor-1 Signaling in Metastatic Pancreatic Cancer Phase Ib and Randomized Phase II Trial of Gemcitabine, Erlotinib, and Cixutumumab Versus Gemcitabine Plus Erlotinib (SWOG S0727)
Philip A. Philip et al.
CANCER (2014)
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2014)
Pancreatic Adenocarcinoma
David P. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Evidence for the Importance of Personalized Molecular Profiling in Pancreatic Cancer
Loukia N. Lili et al.
PANCREAS (2014)
Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies
Agnieszka Anna Rucki et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer
Dana B. Cardin et al.
CANCER MEDICINE (2014)
IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer
Toshiki Hirakawa et al.
BMC CANCER (2013)
Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas
Cheng Ean Chee et al.
ONCOLOGIST (2013)
The WNT signaling pathway from ligand secretion to gene transcription: Molecular mechanisms and pharmacological targets
Hoeke A. Baarsma et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Notch signaling in pancreatic cancer: oncogene or tumor suppressor?
Jacqueline L. Avila et al.
TRENDS IN MOLECULAR MEDICINE (2013)
Pancreatic cancer: why is it so hard to treat?
Paul E. Oberstein et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2013)
Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer
Jiujie Cui et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
Antonella De Luca et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks
Yu Kataoka et al.
INVESTIGATIONAL NEW DRUGS (2012)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Andrew V. Biankin et al.
NATURE (2012)
TGF-β-induced epithelial-mesenchymal transition: A link between cancer and inflammation
Jonas Fuxe et al.
SEMINARS IN CANCER BIOLOGY (2012)
PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
Lise Willems et al.
CURRENT ONCOLOGY REPORTS (2012)
Signal Transduction by Vascular Endothelial Growth Factor Receptors
Sina Koch et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
M402, a Novel Heparan Sulfate Mimetic, Targets Multiple Pathways Implicated in Tumor Progression and Metastasis
He Zhou et al.
PLOS ONE (2011)
Molecular Predictors of Outcome in a Phase 3 Study of Gemcitabine and Erlotinib Therapy in Patients With Advanced Pancreatic Cancer National Cancer Institute of Canada Clinical Trials Group Study PA 3
Gilda da Cunha Santos et al.
CANCER (2010)
Targeting Notch signaling in pancreatic cancer
Elodie Ristorcelli et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer
Taro Matsuzaki et al.
CANCER SCIENCE (2009)
Wnt signalling and cancer stem cells
Jesus Espada et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
Jennifer M. Bailey et al.
CLINICAL CANCER RESEARCH (2008)
Targeting angiogenesis in pancreatic cancer: rationale and pitfalls
Chery Whipple et al.
LANGENBECKS ARCHIVES OF SURGERY (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hedgehog/Ras interactions regulate early stages of pancreatic cancer
Marina Pasca di Magliano et al.
GENES & DEVELOPMENT (2006)
Genetics and biology of pancreatic ductal adenocarcinoma
Aram F. Hezel et al.
GENES & DEVELOPMENT (2006)
Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy
T Helleday et al.
CELL CYCLE (2005)
Epithelial differentiation in pancreatic development and neoplasia - New niches for nestin and notch
SD Leach
JOURNAL OF CLINICAL GASTROENTEROLOGY (2005)
Missense mutations of MADH4:: Characterization of the mutational hot spot and functional consequences in human tumors
CA Iacobuzio-Donahue et al.
CLINICAL CANCER RESEARCH (2004)
The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells
T Asano et al.
ONCOGENE (2004)
Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
H Safran et al.
CANCER INVESTIGATION (2004)
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
SR Hingorani et al.
CANCER CELL (2003)
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
SP Thayer et al.
NATURE (2003)
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer - Potential therapeutic targets
ES Calhoun et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Incidence, mechanism and prognostic value of activated AKT in pancreas cancer
MG Schlieman et al.
BRITISH JOURNAL OF CANCER (2003)
Small molecule modulation of Smoothened activity
JK Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Pharmaceutical intervention in the JAK/STAT signaling pathway
HM Seidel et al.
ONCOGENE (2000)
分享论文
